Avalo Therapeutics, Inc.
AVTX
59 insider filings · Latest: Sep 30, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Mar 18 8:07 PM | Mittie DoyleChief Medical Officer | Sale | 25,492 | $16.15 | $411.6K | 3,622(D) | View → |
| Mar 16, 2026 | Mar 16 8:39 PM | MITTIE DOYLE | Proposed Sale | 29,529 | $15.80 | $466.6K | — | View → |
← Previous
Page 3 of 3
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Mar 28, 2026 | Mar 31 8:09 PM | Jonathan GoldmanDirector | Option Exercise | 3,166 | — | 3,167(D) | View → |
| Mar 16, 2026 | Mar 18 8:07 PM | Mittie DoyleChief Medical Officer | Option Exercise | 25,492 | $12.65 | 149,008(D) | View → |
| Feb 26, 2026 | Mar 2 9:24 PM | Paul VarkiChief Legal Officer | Grant/Award | 80,000 | $17.64 | 80,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:23 PM | Jennifer RileyChief Strategy Officer | Grant/Award | 95,000 | $17.64 | 95,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:23 PM | Mittie DoyleChief Medical Officer | Grant/Award | 105,000 | $17.64 | 105,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:22 PM | Taylor BoydChief Business Officer | Grant/Award | 95,000 | $17.64 | 95,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:22 PM | Christopher Ryan SullivanChief Financial Officer | Grant/Award | 105,000 | $17.64 | 105,000(D) | View → |
| Feb 26, 2026 | Mar 2 9:20 PM | Garry Arthur NeilDirector, Chief Executive Officer | Grant/Award | 286,000 | $17.64 | 286,000(D) | View → |
← Previous
Page 3 of 3